Wall Street’s appetite for biotechnology stocks has a familiar starting point: promising science with the potential to become a profitable medicine. In 2026, advances in drug development and renewed acquisition activity have strengthened the sector’s appeal. Cancer treatments, genetic disorders, autoimmune diseases, and obesity therapies offer distinct opportunities, giving investors several ways to follow the next wave of healthcare innovation.
The commercial stakes are substantial. Goldman Sachs Research raised its forecast for global obesity-drug sales in 2030 by 15% to $114 billion, with oral medications expected to capture 40% of that market. That shift could broaden a treatment category historically dominated by injections, illustrating how a change in drug delivery can reshape an entire pharmaceutical market.
Patent Expirations Put Biotech Pipelines in the Spotlight
Behind the biotechnology industry’s deal-making surge lies a less glamorous reality: even blockbuster medicines eventually lose patent protection. Reuters reported that more than $300 billion in pharmaceutical revenue faces potential loss of exclusivity over the next five years. Buying promising drug candidates offers established manufacturers a way to replenish their pipelines, helping explain why first-quarter biotech mergers and acquisitions reached $84 billion, versus $44.4 billion a year earlier. Oncology, immunology, neuroscience, and obesity remain prominent areas of interest.
Artificial intelligence adds another dimension. Its potential to improve research productivity and support drug discovery is attracting attention alongside advances in targeted therapies and metabolic disease treatments.
Biotech Stocks Under $10 Require a Closer Look
For investors researching biotech stocks under $10, however, a low share price tells only part of the story. Share count, debt, and cash reserves influence valuation, while clinical trial results and regulatory decisions can rapidly change a drug developer’s outlook.
The more useful screening questions concern clinical evidence, treatment differentiation, and cash runway—the time available before additional financing becomes necessary. Small-cap biotech stocks may offer exposure to emerging therapies, but a credible investment thesis also needs a realistic path through clinical development, regulatory approval, and eventual commercialization.
CHECK THIS OUT: Top 6 Small-Cap Healthcare Stocks to Buy Right Now and 5 No-Brainer Healthcare Stocks to Buy Now.
Our Methodology
To identify the 10 best biotech stocks under $10, we used stock screeners to find biotechnology companies with market capitalizations above $1 billion and share prices below $10, then selected and ranked 10 stocks in ascending order by the number of elite hedge funds holding stakes in Q2 2026.
10 Best Biotech Stocks Under $10 to Buy Now
10. Immatics N.V. (NASDAQ:IMTX)
Number of Hedge Fund Holders: 26
Market Capitalization: $1.11 billion
Share Price: $7.26
Immatics N.V. (NASDAQ: IMTX) enters this ranking with a clinical pipeline focused on targeted cancer immunotherapies. Its shares had declined approximately 30% in 2026, according to the supplied market data, creating a gap between the stock’s performance and the development progress investors are watching.
The lead program, anzu-cel, is an investigational cell therapy targeting the PRAME-HLA complex. Updated Phase 1b results in metastatic melanoma showed a 56% confirmed objective response rate, alongside a median response duration of 14.6 months. Those findings offer encouraging evidence of antitumor activity, although larger, later-stage studies remain essential to establishing the treatment’s benefit.
The company is also developing IMA203CD8 for PRAME-positive cancers. Its reported gynecologic-cancer dataset showed a 63% objective response rate and a 50% confirmed response rate, supporting further investigation in difficult-to-treat tumors. The distinction matters: an initial response must meet follow-up requirements before it is classified as confirmed.
Financial resources provide another part of the investment case. Cash, cash equivalents, and other financial assets totaled $448.2 million at June 30, with management projecting funding into 2028. That gives the business room to advance clinical trials while preparing for potential commercialization.
On October 13, Stifel initiated coverage with a Buy rating and a $15 price target, highlighting the melanoma opportunity. The analyst view adds support, but the decisive milestones remain clinical results and the regulatory pathway.
Ranking rationale: Immatics N.V. (NASDAQ: IMTX) ranks tenth with 26 hedge-fund holders, the lowest count in this group. Its inclusion rests on its cancer immunotherapy pipeline, encouraging response data, and financial capacity to support upcoming development milestones.
